Allogeneic hematopoietic SCT following myeloablative conditioning is associated with a high nonrelapse mortality and usually reserved for young, medically fit patients. The use of allogeneic stem cells is associated with a less risk of relapse, but is also associated with the risk of GVHD. The increased antitumor activity is due to graft-vs-tumor immune responses. The newer use of nonmyeloablative or reducedintensity conditioning has decreased the toxicity of this approach and allows the treatment of older patients or those with medical comorbidities that preclude the use of a myeloablative regimen. A nonmyeloablative regimen using fludarabine and 2 Gy TBI was developed in Seattle that reliably allows allogeneic engraftment from either matched related or unrelated donor stem cell sources. Here we describe our results using this regimen in multicenter studies for the treatment of aggressive non-Hodgkin's lymphoma (NHL) and mantle cell NHL.
Introduction
High-dose therapy with autologous hematopoietic SCT (HSCT) is standard treatment for patients with relapsed chemotherapy-sensitive aggressive non-Hodgkin's lymphoma (NHL) who are able to tolerate the therapy, and appears to be curative for 20-50% of patients with diffuse large Bcell histology. The use of an allogeneic donor provides a tumor-free stem cell graft, cells that have not been damaged by prior chemotherapy and the opportunity for graft-vstumor immune responses. This, however, also comes with the increased risk of nonrelapse mortality (NRM) primarily due to GVHD or infections related to GVHD therapy. In most situations, autologous transplantation has been preferred due to much lower NRM (o10%). The use of allogeneic stem cell sources is often reserved for patients with poor marrow function or those with aggressive lymphoma, and usually reserved for younger patients without comorbidities. Older patients or patients who have previously failed high-dose therapy and autologous transplantation have had unacceptably high NRM with myeloablative allogeneic transplants. The recognition that reduced-intensity conditioning and postgrafting immunosuppression could reliably allow allogeneic engraftment with less NRM has brought allogeneic transplantation to older patients and/or younger patients who had failed prior autologous transplantation. In Seattle, under the direction of Rainer Storb, a truly nonmyeloablative regimen was developed based on 90 mg/m 2 fludarabine and 2 Gy TBI with postgrafting immunosuppression with cyclosporine and mycophenolate mofetil. 1 This regimen has now been widely used in a consortium of institutions throughout the United States and the world for the treatment of hematologic malignancies. Here we review our experience with the treatment of patients with aggressive histology lymphomas.
Nonmyeloablative allogeneic HCT for aggressive NHL (diffuse large B-cell NHL)
Forty patients with relapsed or refractory aggressive NHL were treated with this regimen and received allogeneic HCT from related (n ¼ 27) or unrelated donors (n ¼ 13). 2 Patients with bulky, rapidly progressive lymphoma were not eligible as this approach utilizes minimal conditioning and requires 1-3 months to develop graft-vs-tumor effects. Lymphoma histologies included diffuse large B-cell NHL (n ¼ 31), Burkitt's lymphoma (n ¼ 1) and T-cell lymphoma (n ¼ 8). Ten of these patients had disease transformed from follicular NHL (n ¼ 6), Hodgkin's lymphoma (n ¼ 3) or Waldenstrom's macroglobulinemia (n ¼ 1). The median age of the patient was 51 years (range 17-72 years), the median number of prior chemotherapy regimens was 4 and 21 patients had relapsed after high-dose autologous transplant. Seventeen patients were in CR and 12 had chemotherapy-refractory disease at the time of HCT. All patients engrafted and 82% achieved full donor T-cell chimerism (495%) by day 28 post-transplant. Recipients of unrelated grafts achieved more rapid full donor chimerism compared with recipients of related grafts. Eighty-five percent of the patients did not require a platelet transfusion. The incidence rates of grades II, III and IV acute GVHD were 35, 15 and 5%, respectively, and the 2-year estimated probability of chronic GVHD was 45%. The response rate in patients with measurable disease at HCT was 60% in those whose disease was chemotherapy sensitive and 27% in those whose disease was refractory. None of the responding patients had disease relapse with a median follow-up of 25 months. Overall relapse rates were 38% at 1 year and 40% at 2 years. The rates of 100-day and 2-year NRM were 10 and 21%, respectively. The KaplanMeier probabilities of overall survival and progression-free survival at 2 years were 49 and 39%, respectively. Disease status (CR/partial remission) and chemotherapy sensitivity were the strongest predictors of outcome with respect to relapse, overall survival and progression-free survival.
Nonmyeloablative allogeneic HCT for mantle cell NHL
We have published our initial experience with the use of this regimen for patients with relapsed mantle cell NHL. 3 Thirty-three patients (n ¼ 16 related, n ¼ 17 unrelated) received allogeneic HCT using the fludarabine and 2 Gy TBI regimen in seven academic centers associated with the Fred Hutchinson Cancer Research Center in Seattle. Fourteen patients had failed prior high-dose therapy and autologous transplant. The incidence rates of grades II, III and IV acute GVHD were 27, 17 and 13, respectively, and the incidence rate of chronic GVHD was 64%, Surprisingly, antitumor activity was observed with an overall response rate of 85% in the 20 patients with measurable disease at the time of transplantation. This included 75% CRs and 10% partial remissions. Only three patients had progressive disease. The responses were durable with only 9% relapse-related mortality at 2 years. NRM was 24% at 2 years. For the entire group, the probabilities of overall survival and disease-free survival at 2 years were 65 and 60%, respectively. There was a slightly higher overall survival and progression-free survival in recipients of unrelated donor grafts. In several patients, dramatic antitumor effects were observed, including patients who had rapidly failed a prior high-dose regimen and autologous transplant. This suggests that mantle cell NHL is quite sensitive to graft-mediated antitumor effects.
Conclusion
Treatment of older patients or those who have previously failed high-dose therapy with an allogeneic hematopoietic transplant following nonmyeloablative conditioning is a promising new therapy that can be offered with a less risk of NRM. For aggressive lymphomas such as diffuse large B-cell NHL, chemosensitivity and cytoreduction to a minimal disease state are optimal to allow the emergence of graft-vs-tumor immune responses before the development of progressive disease. Augmentation of conditioning with a tumor-specific therapy such as radiolabeled qanti-CD20 antibodies may allow greater initial tumor control for patients with refractory disease and is ongoing at our center. 4 In contrast, mantle cell NHL, despite the poor outcome with standard therapy, appears particularly sensitive to graft-vs-tumor immune responses. Significant NRM is still observed and is increased by comorbidities present at the time of transplant. 5 This requires careful patient counseling to determine the optimal timing to consider the risks and benefits of transplant. Eventually, better treatment for GVHD and methods to augment graft-vs-tumor without GVHD are needed to further reduce NRM and decrease the risk of relapse.
